Drug Trial Radar · NCT05026398
Fenfluramine and Cognition
Last checked: Nov 20, 2026Latest source record: Nov 15, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
56
Actual
Start
Apr 12, 2021
Primary completion
Jun 22, 2022
Study completion Jun 22, 2022
Sponsor
- Lead sponsor
- University of OxfordAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Zogenix International Limited, Inc., a subsidiary of Zogenix, Inc.; National Institute for Health Research, United Kingdom
- First posted
- Aug 30, 2021
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Other
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 22 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
In this study, the investigators will investigate the cognitive effects of fenfluramine, a drug that directly stimulates the release of serotonin in the brain and positively modulates σ1 function. The investigators will use fenfluramine to assess the cognitive effects of modulating serotonin and σ1 function in healthy volunteers using a battery of cognitive tasks that measure learning and memory, executive functioning, reward processing, and emotional processing. The study design is double-blind, and participants will be randomised to either seven days of fenfluramine or placebo administration. All participants will attend two screening visits to assess eligibility. There are two main study visits; during the first, participants will undertake cognitive tasks and questionnaires before taking the initial study dose. One the second study visit, participants will once again complete these tasks and questionnaires after a week of fenfluramine/placebo administration.
Conditions
- Cognitive Function
Interventions
FenfluramineDrug
Fenfluramine (30mg daily) will be dispensed in a cherry flavoured aqueous solution. Fenfluramine is both a serotonin releasing agent and sigma-1 receptor agonist. Fenfluramine is FDA approved for the treatment of Dravet syndrome, a rare form of epilepsy.
PlaceboOther
The placebo is a liquid designed to be identical to the interventional drug fenfluramine in terms of both taste and visual appearance. It will be administered at 30mg daily and dispensed in a cherry flavoured aqueous solution
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in Go/No-Go Task performanceTime frame: Immediately before initial dose (Day 1) and immediately before final visit (Day 7)
- Change in Auditory Verbal Learning TaskTime frame: Immediately before initial dose (Day 1) and immediately before final visit (Day 7)
- Change in N-back task performanceTime frame: Immediately before initial dose (Day 1) and immediately before final visit (Day 7)
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Department of Psychiatry, University of Oxford
Oxford, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.